期刊名称：SIGNAL TRANSDUCTION AND TARGETED THERAPY ISSN： 2095-9907 出版频率： Continuous publication 出版社： SPRINGERNATURE, CAMPUS, 4 CRINAN ST, LONDON, ENGLAND, N1 9XW   出版社网址： https://www.nature.com/ 期刊网址： https://www.nature.com/sigtrans/ 影响因子： 18.187 主题范畴： BIOCHEMISTRY & MOLECULAR BIOLOGY;    CELL BIOLOGY;    China Journals 变更情况： 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal Signal Transduction and Targeted Therapy (ISSN 2059-3635 (online), ISSN 2095-9907 (print), CN 51-1758/R) is an open access journal, which aims to accomplish timely publication of the latest discoveries and progress in both basic science and clinical research related to signal transduction and targeted therapy. It will include research on major human diseases, such as cancer, autoimmune disorders and others.  Signal Transduction and Targeted Therapy is a multidisciplinary journal, covering topics including but not limited to molecular biology, cell biology, pharmacology, medicinal chemistry, computational chemistry, systems biology, bioinformatics, and clinical medicine. The editorial team of Signal Transduction and Targeted Therapy is composed of a highly respected editorial board of researchers from across the globe, led by the internationally renowned Professor Carlo M. Croce, together with Professor Kang Zhang and Professor Yu-Quan Wei. This journal is now indexed in Science Citation Index Expanded (SCIE), Journal Citation Reports/Science Edition, BIOSIS previews, Directory of Open Access Journals (DOAJ), MEDLINE, PubMed Central (PMC) and Scopus. Aims & Scope Signal Transduction and Targeted Therapy is an international, peer-reviewed, open-access journal that publishes original research articles and review articles related to all aspects of signal transduction in physiological and pathological processes, as well as signal transduction-targeted therapeutics in the form of biological agents and small molecular drugs used to treat human diseases such as cancer, autoimmune disorders, and others. This journal focuses on cutting-edge advances both experimentally and clinically.   Instructions to Authors Online Submission To find out about how to submit an article to Signal Transduction and Targeted Therapy, please read the journal’s specific Guide for Authors. If your manuscript contains supplementary materials, please also refer to the template for supplementary materials.  If you are ready to submit an article to Signal Transduction and Targeted Therapy, please use our online journal manuscript tracking system. Please note: For questions or technical difficulties related to the manuscript tracking system, please contact the Helpdesk (not the editorial office) via this page. Springer Nature has introduced improvements to the manuscript tracking system used on many of our journals, designed to streamline your accounts with Springer Nature journals and conveniently provide you with more information in one place. More information is provided when you log into the manuscript tracking system. Editorial Board Editors-in-Chief Prof. Carlo M. Croce, Institute of Genetics, The Ohio State University, Columbus, Ohio, USA Prof. Carlo M. Croce (M.D.) was born in 1944. He received his B.S. and M.D. degrees from University of Rome in 1967 and 1969, respectively. In 1970, he joined the Wistar Institute of Anatomy and Biology as an associate scientist. He became a faculty member in 1971, and was promoted to professor in 1976 and associate director in 1980. In 1991, Dr. Croce was recruited as director of Kimmel Cancer Institute/Kimmel Cancer Center, Thomas Jefferson University. In 2004, Dr. Croce became John W. Wolfe Chair in Human Cancer Genetics, Chairman of the Department of Molecular Virology, Immunology and Medical Genetics, and Director of the Institute of Genetics, The Ohio State University. He has published more than 1000 papers in international journals including Science, Nature, Cell, New Engl J Med, JAMA, and Cancer Cell. His research has yielded 62 issued U.S. patents. Dr. Croce is a member of the American Academy of Arts and Sciences, the American Association for the Advancement of Science, The National Academy of Sciences, the Institute of Medicine, and AACR Academy. He was an Editor-in-Chief of Cancer Research (1990-1999). Prof. Kang Zhang, Center for Biomedicine and Innovations at Faculty of Medicine, Macau University of Science and Technology, China Kang Zhang, MD, PhD is the Professor and Director of Center for Biomedicine and Innovations at Faculty of Medicine, Macau University of Science and Technology.  Dr. Zhang obtained his M.D. with Magna Cum Laude honors from Harvard Medical School and MIT joint MD program and his PhD in genetics from Harvard University. He did his postdoctoral training also at Harvard.  He completed his residency in ophthalmology at Johns Hopkins University and his retina surgery fellowship at University of Utah. He was a faculty member at Johns Hopkins University, Cleveland Clinic Foundation, University of Utah, and University of California San Diego. Among his honors include AAAS fellow, fellow of American Institute for Medical and Biological Engineering, memberships in Association of American Physicians and American Society of Clinical Investigation; Outstanding Achievement Award of Chinese Ophthalmological Society, Burroughs Wellcome Clinical Scientist Award in Translational Research; Lew R. Wasserman Merit Award and Senior Investigator Award from Research to PreventBlindness; Johns Hopkins Medical Institutions Clinician Scientist Award, the World Ophthalmologist 100 Powerlist, American’s Top Ophthalmologists, Elsevier highly Cited Scholar (2019). Dr. Zhang has published over 200 peer-reviewed manuscripts in top peer-reviewed journals- covering a wide range of topics in genetics, epigenetics, stem cells, nano-engineering and 3D printing, clinical trials, and artificial intelligence. He has more than 26,000 citations and an h-index of 80. His discovery that HTRA1 is a major susceptibility gene for age-related macular degeneration is listed as one of “top-ten breakthroughs in 2006” by Science Magazine. Prof. Yu-Quan Wei, National/State Key Laboratory of Biotherapy and Clinical Cancer Center, West China Hospital, West China Medical School, Sichuan University, China  Yu-quan Wei, Ph.D., Professor and Director of National/State Key Laboratory of Biotherapy and Clinical Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu. He was educated at West China University of Medical Sciences for a bachelor's degree in Medicine and a Master's Degree in Medicine, and educated at Kyoto University in Japan for Doctoral Degree. His major research interests include: targeted therapy, signal transduction, gene and cell therapy, and cancer vaccines. He has published more than 300 papers in international journals including Nat Med, Nat Commun, PNAS, Blood, Cancer Res, Clinic Cancer Res, J Immunol, and J Biol Chem, etc. He was selected as an academician of Chinese Academy of Sciences in 2003. He is now President of China Medicinal Biotech Association. He has served as an associate editor of Human Gene Therapy and Editorial Board Member of several International Journals. Associate Editors  Rami I. Aqeilan, Milton Winograd Chair in Cancer Research, Lautenberg Center for Immunology and Cancer Research, Hebrew University of Jerusalem, Israel Ashley Bush, University of Melbourne, Australia Xuetao Cao, Chinese Academy of Medical Science, China Webster K. Cavenee, Ludwig Institute for Cancer Research University of California, San Diego, USA Xin-yuan Fu, National University of Singapore, Singapore ​Guangping Gao, Microbiology and Physiological Systems, University of Massachusetts Medical School, Massachusetts, USA Curtis Harris,  Laboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, USA Zhen Huang, Department of Chemistry & Department of Biology, Georgia State University, Atlanta, Georgia, USA Yibin Kang, Princeton University, USA Weimin Li, West China Hospital, Sichuan University, China Yang Liu, Center for Cancer and Immunology Research, Children's National Medical Center, Washington DC, USA Qing Richard Lu, Brain Tumor Center, Cincinnati Children's Hospital Medical Center, USA Pralay Maiti, Indian Institute of Technology, Banaras Hindu University, India Zhiyong Qian, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, China Dalla-Favera Riccardo, Cancer Center, Columbia University; Department of Pathology & Cell Biology, Columbia University, USA Hongbing Shu, Wuhan University, China, Shao-Cong Sun, University of Texas, MD Anderson Cancer Center, USA Philip N Tsichlis, Molecular Oncology Research Institute, Tufts Medical Center, USA Peter K. Vogt, The Scripps Research Institute, USA Rong Xiang, Nankai University, China Zhixiong Xiao, College of Life Sciences, Sichuan University, China Shengyong Yang, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, China Editorial Board Members Xiuwu Bian, Armed Forces Institute of Pathology, Network Center of Third Military Medical University, Chongqing, China Guojun Bu, Department of Neuroscience, Mayo Clinic, USA Shawn Burgess, National Human Genome Research Institute, National Institutes of Health, USA John C. Byrd, The Ohio State University, USA George A. Calin, MD Anderson Cancer Center, USA Thomas Carell, Ludwig-Maximilians-Universität München, Germany Chong Chen, West China Hospital, Sichuan University, China Guoqiang Chen, School of Medicine, Shanghai Jiao Tong University, China Zhijian Chen, UT Southwestern Medical Center,USA Eros Lazzerini Denchi, The Scripps Research Institute, La Jolla, USA Miguel Sena Esteves, University of Massachusetts Medical School, USA David Fruman, University of California, Irvine, USA Caiyun Fu, Zhejiang Sci-Tech University, China Xiangdong Fu, Univerisity of California, San Diego, USA Alan Garen, School of Medicine, Yale University, USA Mark Ginsberg, University of California, San Diego, USA JunLin Guan, Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, USA Junhong Han, West China Hospital, Sichuan University, China Stephen Hann, Vanderbilt University, Nashville, USA Ming-Liang He, City University of Hong Kong, China Nongyue He, School of Biological Science and Medical Engineering, Southeast University, China Matthew Vander Heiden, Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, USA Philip W. Hinds, Tufts University School of Medicine, USA Ying Hu, Harbin Institute of Technology, China Canhua Huang, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, China Wendong Huang, Department of Diabetes Complications and Metabolism, City of Hope National Medical Center, USA Shile Huang, Louisiana State University Health Sciences Center, USA Lijun Jia, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, China Hualiang Jiang, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China JianSheng Kang, Zhengzhou University, China Tiebang Kang, Sun Yat-Sen University Cancer Center, China Kazunori Kataoka, The University of Tokyo, Japan Guido Kroemer, Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, France Peng Lei, West China Hospital, Sichuan University, China Qun-Ying Lei, Shanghai Medical College, Fudan University, China Luyuan Li, State key laboratory of medicinal chemical biology, Nankai University, Tianjin, China Haitao Li, Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China Lei Li, MD Anderson Cancer Center, USA Jinsong Li, Institute of Biochemistry and Cell Biology, Shanghai Institutes for biological Science, CAS, China Guomin Li, University of Texas Southwestern Medical Center, USA Wenbin Li, Beijing Tiantan Hospital, Capital Medical University, China Shengcai Lin, School of Life Sciences, Xiamen University, China Shuo Lin, Department of Molecular, Cell & Developmental Biology, University of California, USA Feng Lin, Cleveland Clinic Lerner Research Institute, USA Lin Liu, College of Life Sciences, Nankai University, Tianjin, China Mofang Liu, Shanghai Institute of Biochemistry and Cell Biology, CAS, China Yu Liu, West China Hospital, Sichuan University, China Nathan Luedtke, University of Zurich, Switzerland Pralay Maiti, Indian Institute of Technology (Banaras Hindu University), India Guido Marcucci, City of Hope Comprehensive Cancer Center, USA Ruggero De Maria, Istituto Superiore di Sanita, Italy Ingo Mellinghoff, Memorial Sloan-Kettering Cancer Center, New York, USA Hongming Miao, Army Medical University, China Karl Munger, Tufts University School of Medicine, USA Liang Ouyang, West China Hospital, Sichuan University, China  Lianghu Qu, Sun Yat-sen University, China Zihe Rao, Tsinghua University, China Steve Rokita, Johns Hopkins University, USA Kanaga Sabapathy, Duke University, USA Erwei Song, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, China Bing Su, Shanghai Institute of Immunology, Shanghai JiaoTong University School of Medicine, China Ming Tan, USA Mitchell Cancer Institute, USA Yongguang Tao, Central South University, China David Tuveson, Cold Spring Habor Laboratory, USA Daowen Wang, Huazhong University of Science and Technology, China Xiaofan Wang, Duke University, USA Yongsheng Wang, West China Hospital, Sichuan University Min Wu, Department of Basic Sciences, University of North Dakota, USA Hao Wu, Harverd Medical School and Boston Children's Hospital, USA Di Xia, National Institutes of Health, USA Xiao Xiao, Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, USA Huaxi Xu, Sanford Burnham Prebys Medical Discovery Institute, USA Tian Xu, Howard Hughes Medical Institute & Yale University School of Medicine, USA Xianjie Yang, UCLA School of Medicine, USA Pengyuan Yang, Institutes of Biomedical Sciences, Fudan University, China Dihua Yu, The University of Texas MD Anderson Cancer Center, USA Junying Yuan, Department of Cell Biology，Harvard Medical School, USA Qimin Zhan, State Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China Zhiguo Zhang, Columbia University, USA Shimin Zhao, State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai , China Pan Zheng, Children's National Medical Center, USA Weimin Zhong, Yale University, USA Chenchen Zhou, West China School of Stomatology, Sichuan University, China Qi Zhou, State Key Laboratory of Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, China Weiguo Zhu, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Biochemistry and Molecular Biology, Peking University Health Science Center, China